Medtech Acquisition Corp Stock Current Valuation
| MTACUDelisted Stock | USD 9.86 0.00 0.00% |
Valuation analysis of Medtech Acquisition Corp helps investors to measure Medtech Acquisition's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Medtech Acquisition's price fluctuation is very steady at this time. Calculation of the real value of Medtech Acquisition Corp is based on 3 months time horizon. Increasing Medtech Acquisition's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Medtech Acquisition's intrinsic value may or may not be the same as its current market price of 9.86, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.86 | Real 8.47 | Hype 9.86 | Naive 9.95 |
The intrinsic value of Medtech Acquisition's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Medtech Acquisition's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Medtech Acquisition Corp helps investors to forecast how Medtech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medtech Acquisition more accurately as focusing exclusively on Medtech Acquisition's fundamentals will not take into account other important factors: Medtech Acquisition Corp Company Current Valuation Analysis
Medtech Acquisition's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Medtech Acquisition Current Valuation | 81.09 M |
Most of Medtech Acquisition's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medtech Acquisition Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Medtech Acquisition Corp has a Current Valuation of 81.09 M. This is 99.75% lower than that of the Capital Markets sector and significantly higher than that of the Financials industry. The current valuation for all United States stocks is 99.51% higher than that of the company.
Medtech Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medtech Acquisition's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medtech Acquisition could also be used in its relative valuation, which is a method of valuing Medtech Acquisition by comparing valuation metrics of similar companies.Medtech Acquisition is currently under evaluation in current valuation category among its peers.
Medtech Fundamentals
| Return On Asset | -0.0193 | |||
| Current Valuation | 81.09 M | |||
| Price To Earning | 39.61 X | |||
| EBITDA | (8.58 M) | |||
| Net Income | 5.54 M | |||
| Cash And Equivalents | 69.18 K | |||
| Total Debt | 2.37 M | |||
| Debt To Equity | 1.77 % | |||
| Current Ratio | 0.15 X | |||
| Book Value Per Share | (2.42) X | |||
| Cash Flow From Operations | (2.74 M) | |||
| Earnings Per Share | 0.26 X | |||
| Beta | -0.0423 | |||
| Market Capitalization | 306.25 M | |||
| Total Asset | 20.19 M | |||
| Retained Earnings | (13.27 M) | |||
| Working Capital | (2.14 M) | |||
| Z Score | 75.01 | |||
| Net Asset | 20.19 M |
About Medtech Acquisition Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medtech Acquisition Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medtech Acquisition using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medtech Acquisition Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Medtech Stock
If you are still planning to invest in Medtech Acquisition Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medtech Acquisition's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |